A randomized, placebo-controlled trial of the use of an inhibitor of Aquaporin-1 for the treatment of heart failure with preserved ejection fraction-the BACOPEF trial
2020
Bruxelles
Soutien au projet 'A randomized, placebo-controlled trial of the use of an inhibitor of Aquaporin-1 for the treatment of heart failure with preserved ejection fraction-the BACOPEF trial'.
Soutien
79.587 €
Restez informé.e des nouveaux individus ou organisations soutenus
